{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05305287",
            "orgStudyIdInfo": {
                "id": "HSC20210284H"
            },
            "secondaryIdInfos": [
                {
                    "id": "1R01DK129676-01A1",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1R01DK129676-01A1"
                }
            ],
            "organization": {
                "fullName": "The University of Texas Health Science Center at San Antonio",
                "class": "OTHER"
            },
            "briefTitle": "Quantifying Hepatic Mitochondrial Fluxes in Humans",
            "officialTitle": "Quantitation of Hepatic Mitochondrial Fluxes in Humans With Nonalcoholic Fatty Liver Disease (NAFLD)",
            "therapeuticArea": [
                "Endocrinology",
                "Other",
                "Gastroenterology"
            ],
            "study": "quantifying-hepatic-mitochondrial-fluxes-in-humans"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-03-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-22",
            "studyFirstSubmitQcDate": "2022-03-22",
            "studyFirstPostDateStruct": {
                "date": "2022-03-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-21",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Luke Norton",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "The University of Texas Health Science Center at San Antonio"
            },
            "leadSponsor": {
                "name": "The University of Texas Health Science Center at San Antonio",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone",
            "detailedDescription": "The study team will examine hepatic mitochondrial TCA flux and pyruvate cycling (oral \\[U-13C\\]-propionate), hepatic gluconeogenesis (oral 2H2O), and hepatic insulin sensitivity (intravenous \\[3,4-13C2\\]-glucose with euglycemic insulin clamp) before and after 16 weeks treatment with the FDA approved insulin sensitizer pioglitazone. These studies will be performed in (i) type 2 diabetic subjects with NAFL but without evidence of fibrosis, and (ii) type 2 diabetic patients with NASH. Liver biopsies will be obtained before and after treatment for the diagnosis of NAFL/NASH and for molecular analyses."
        },
        "conditionsModule": {
            "conditions": [
                "Non-Alcoholic Fatty Liver Disease",
                "Type 2 Diabetes",
                "Mitochondrial Metabolism Disorders"
            ],
            "keywords": [
                "NAFLD",
                "Diet",
                "Exercise"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Patients with T2D and NAFL or NASH will be randomly assigned to receive placebo or pioglitazone treatment groups.",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "NAFL TZD",
                    "type": "EXPERIMENTAL",
                    "description": "T2D with non-alcoholic fatty liver (NAFL), treated with pioglitazone",
                    "interventionNames": [
                        "Drug: Pioglitazone"
                    ]
                },
                {
                    "label": "NAFL Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "T2D with non-alcoholic fatty liver (NAFL), treated with placebo",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                },
                {
                    "label": "NASH TZD",
                    "type": "EXPERIMENTAL",
                    "description": "T2D with non-alcoholic steatohepatitis (NASH), treated with pioglitazone",
                    "interventionNames": [
                        "Drug: Pioglitazone"
                    ]
                },
                {
                    "label": "NASH Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "T2D with non-alcoholic steatohepatitis (NASH), treated with placebo",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Pioglitazone",
                    "description": "An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.",
                    "armGroupLabels": [
                        "NAFL TZD",
                        "NASH TZD"
                    ],
                    "otherNames": [
                        "Actos"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Placebo for pioglitazone",
                    "armGroupLabels": [
                        "NAFL Placebo",
                        "NASH Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Effect of pioglitazone on hepatic mitochondrial TCA cycle fluxes",
                    "description": "Quantitated using a combine stable isotope approach before and after treatment with pioglitazone",
                    "timeFrame": "Baseline, week 16"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Mean absolute change from baseline in liver fat content by magnetic resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)",
                    "description": "Mean absolute change from baseline in liver fat content by MRI-PDFF",
                    "timeFrame": "Baseline, Week 16"
                },
                {
                    "measure": "Mean change from baseline in body weight",
                    "description": "Mean change from baseline in body weight",
                    "timeFrame": "Baseline, Week 16"
                },
                {
                    "measure": "Mean change from baseline in body composition",
                    "description": "Mean change from baseline in lean and fat mass measured by DEXA",
                    "timeFrame": "Baseline, Week 16"
                },
                {
                    "measure": "Quantitate the effect of pioglitazone on liver histology by improvement of fibrosis",
                    "description": "Percentage of Participants with \u22651 Point Decrease in Fibrosis Stage with No Worsening of NASH on Liver Histology",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Quantitate the effect of pioglitazone on NAFLD Activity Score (NAS)",
                    "description": "Percentage of Participants that Achieve a \u22652 Point Decrease in NAS on Liver Histology, with \u22651 Point Reduction in at Least 2 NAS Components",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Examine the effect of pioglitazone on non-invasive markers of NAFLD",
                    "description": "Mean change from baseline in Fibrosis-4 (FIB-4), transient elastography (Fibroscan\u00ae), NAFLD fibrosis score (NFS), alanine transaminase (ALT) and aspartate transaminase (AST)",
                    "timeFrame": "Baseline, Week 16"
                },
                {
                    "measure": "Effect of pioglitazone on the hepatic lipidome",
                    "description": "Lipidomics will be carried out using mass-spectrometry methods",
                    "timeFrame": "Baseline, Week 16"
                },
                {
                    "measure": "Effect of pioglitazone on hepatic gene regulatory networks",
                    "description": "Multimodal RNA-Seq and ATAC-Seq will be used to examine gene regulatory networks in liver samples",
                    "timeFrame": "Baseline, Week 16"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "T2D with NAFL\n\nInclusion Criteria:\n\n* Confirmed T2D based on OGTT (2 h glucose \u2265200 mg/dl).\n* Treated with diet, metformin, and/or sulfonylurea and in good general health determined by medical history, physical exam, and routine blood chemistries;\n* age = 18-80 years;\n* BMI = 25-40 kg/m2;\n* HbA1c = 7-10%; stable body weight (\u00b14 pounds) over the preceding 3-months;\n* not taking any medication known to affect glucose metabolism other than antidiabetic medications.\n* Evidence of moderate/severe fatty liver (steatosis; grade S2/S3 on FibroScan corresponding to \u226510% fat on MRI-PDFF) and no/minimal hepatic fibrosis (grade F0/F1 on FibroScan).\n\nExclusion Criteria:\n\n* Alcohol consumption \\>14 units/week for women and \\>21 units/week for men.\n* Cirrhosis (fibrosis stage 4).\n* Type 1 diabetes and/or GAD positive subjects.\n* Subjects not drug naive or have been on metformin more than 3 months.\n* Presence of proliferative retinopathy.\n* Urine albumin excretion \\> 300 mg/day.\n* Evidence of other forms of chronic liver disease, including alcoholic liver disease, hepatitis B and C, primary biliary cholangitis, suspected/proven liver cancer and any other liver disease other than NAFLD.\n* History of NY Class III-IV heart failure\n\nT2D with NASH\n\nInclusion Criteria:\n\n* Confirmed T2D based on OGTT (2 h glucose \u2265200 mg/dl).\n* Treated with diet, metformin, and/or sulfonylurea and in good general health determined by medical history, physical exam, and routine blood chemistries;\n* age = 18-80 years;\n* BMI = 25-40 kg/m2;\n* HbA1c = 7-10%;\n* stable body weight (\u00b14 pounds) over the preceding 3-months;\n* not taking any medication known to affect glucose metabolism other than antidiabetic medications.\n* Evidence of moderate/severe fatty liver (steatosis; grade S2/S3 on FibroScan corresponding to \u226510% liver fat on MRI-PDFF) and moderate/severe hepatic fibrosis (grade F2/F3 on FibroScan).\n\nExclusion Criteria:\n\n* Alcohol consumption \\>14 units/week for women and \\>21 units/week for men.\n* Cirrhosis (fibrosis stage 4).\n* Type 1 diabetes and/or GAD positive subjects.\n* Subjects not drug naive or have been on metformin more than 3 months.\n* Presence of proliferative retinopathy.\n* Urine albumin excretion \\> 300 mg/day.\n* Evidence of other forms of chronic liver disease, including alcoholic liver disease, hepatitis B and C, primary biliary cholangitis, suspected/proven liver cancer and any other liver disease other than NAFLD.\n* History of NY Class III-IV heart failure",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Luke Norton, PhD",
                    "role": "CONTACT",
                    "phone": "210-567-0739",
                    "email": "nortonl@uthscsa.edu"
                },
                {
                    "name": "Andrea Hansis-Diarte, MPH",
                    "role": "CONTACT",
                    "phone": "210-567-3208",
                    "email": "hansisdiarte@uthscs.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Luke Norton, PhD",
                    "affiliation": "University of Texas Health Science Center San Antonio",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Texas Diabetes Institute - University Health System",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78207",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andrea Hansis-Diarte, MPh",
                            "role": "CONTACT",
                            "phone": "210-567-6691",
                            "email": "hansisdiarte@uthscsa.edu"
                        },
                        {
                            "name": "Luke Norton, PhD",
                            "role": "CONTACT",
                            "phone": "210-567-0739",
                            "email": "hansisdiarte@uthscsa.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "University of Texas Health Science Center at San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000005234",
                    "term": "Fatty Liver"
                },
                {
                    "id": "D000065626",
                    "term": "Non-alcoholic Fatty Liver Disease"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7119",
                    "name": "Diabetes Mellitus, Type 2",
                    "relevance": "LOW"
                },
                {
                    "id": "M8375",
                    "name": "Fatty Liver",
                    "asFound": "Fatty Liver",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30540",
                    "name": "Non-alcoholic Fatty Liver Disease",
                    "asFound": "Non-alcoholic Fatty Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "asFound": "Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "asFound": "Metabolism Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5868",
                    "name": "Visceral Steatosis",
                    "asFound": "Fatty Liver",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077205",
                    "term": "Pioglitazone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "M1693",
                    "name": "Pioglitazone",
                    "asFound": "Percutaneous",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                }
            ]
        }
    },
    "hasResults": false
}